Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

Table 1 Demographic and disease characteristics of patients

Number of patients	46
Age, years (range)	60.1 ± 13.7 (21–83)
BMI, kg/m²	23.1 ± 3.81
Disease duration, years (range)	8.09 ± 11.3 (1–52)
Stage I, II, III, IV	7, 17, 11, 11
RF, positive, %	71.7
ROM, U.Carr	600 ± 145
CRP, mg/dL	3.78 ± 3.77
MMP-3, ng/mL	374 ± 294
TJC	4.5 ± 4.8
SJC	3.8 ± 3.9
DAS28-ESR	4.82 ± 1.00
CDAI	17.6 ± 9.86
HAQ	0.776 ± 0.579
MTX dose, mg/week (% usage)	8.96 ± 1.53 (82.6)
PSL dose, mg/day (% usage)	5.20 ± 2.32 (58.7)

BMI, body mass index; RF, rheumatoid factor; ROM, reactive oxygen metabolites; CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; TJC, tender joint count; SJC, swollen joint count; DAS, disease activity score; ESR, erythrocyte sedimentation rate; CDAI, clinical disease activity index; MTX, methotrexate; PSL, prednisolone. Values are expressed as mean ± SD

ISSN: 2520-1026